Document is current
Any future updates will be listed below
-
Authors
Buonsenso, Danilo
Cotugno, Nicola
Amodio, Donato
Pascucci, Giuseppe Rubens
Di Sante, Gabriele
Pighi, Chiara
Morrocchi, Elena
Pucci, Alessandro
Olivieri, Giulio
Colantoni, Nicole
Romani, Lorenza
Rotili, Arianna
Neri, Alessia
Morello, Rosa
Sali, Michela
Tremoulet, Adriana
Raffaelli, Francesca
Zampino, Giuseppe
Rossi, Paolo
Valentini, Piero
Palma, Paolo
- License Information
-
More Information
Article History
Received: 6 August 2024
Revised: 12 December 2024
Accepted: 16 December 2024
First Online: 24 January 2025
Competing interests
: D.B. was been granted a non-competitive grant from Pfizer to study Long COVID in children, and has won a grant to study mRNA profile in children with PCC from Roche Italia and ESPID. The funding agencies did not play any role in study design nor in data interpretation. D.B. has participated in educational peer-to-peer programs on Long COVID organized by Pfizer and has participated as invited speaker in a sponsored session of COVID-19 vaccines in children at the ESPID conference in 2022. All the other authors declare no conflicts of interest.
: The Long COVID cohort was enrolled as part of a larger, prospective, multidisciplinary follow-up study of children with SARS-CoV-2 infection, approved by the ethics committee of Fondazione Policlinico Universitario A. Gemelli IRCCS of Rome, Italy (Ethic approval ID4518, Prot0040139/21), and informed consent was provided. Written and informed consent was obtained from parents/caregivers and from children older than 5 years of age, according to local guidance of the ethic committees. SARS-CoV2, MIS-C and HC were enrolled from March to April 2020 at Bambino Gesù Children’s Hospital in Rome for the CACTUS (Immunological studies in Children AffeCTed by COVID and acUte reSpiratory diseases) (Prot. 2083_OPBG_2020). The study was approved by local ethical committee, and written informed consent was obtained from all participants or legal guardians as previously reported.
